EGFR and non-small cell lung carcinoma: Regardless of the identification of a biomarker, the combination of osimertinib with necitumumab, a highly selective monoclonal antibody against EGFR, was shown to be active and safe in patients with advanced EGFR-mutated NSCLC pre-treated with osimertinib in the first-line setting in a phase I study recently presented [103].